MediaPharma Srl is a preclinical stage biotech company focusing on research and development of monoclonal antibodies, Antibody-Drug Conjugates (ADCs) and other products for the treatment of cancer and other severe diseases with high unmet medical needs. At MediaPharma, scientists, doctors and entrepreneurs share the same values and have been working together for years.

Mediapharma has received investment from Filas Spa (Fondo di capitale di rischio) POR FESR 2007/2013, Italian Minister of Economic Development (Fondo Innovazione Tecnologica, FIT), POR FESR Abruzzo 2014-2020, POR FESR 2014-2020 Regione Lazio (Key Enabling Technologies, KET).